Lisata Therapeutics, Inc.
Lisata Therapeutics, Inc., a pioneering biopharmaceutical company headquartered in the United States, is at the forefront of developing innovative therapies for serious diseases. Founded in 2020, Lisata focuses on advancing its proprietary platform to create targeted treatments that address unmet medical needs, particularly in oncology and autoimmune disorders. With a commitment to scientific excellence, Lisata Therapeutics has achieved significant milestones, including the progression of its lead product candidates through various stages of clinical development. The company’s unique approach combines cutting-edge technology with a deep understanding of disease mechanisms, setting it apart in the competitive biopharmaceutical landscape. As it continues to expand its operational reach, Lisata is poised to make a substantial impact on patient care and therapeutic options in the industry.
DitchCarbon Score
How does Lisata Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Lisata Therapeutics, Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Lisata Therapeutics, Inc.'s reported carbon emissions
Lisata Therapeutics, Inc., headquartered in the US, currently does not have any publicly available carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As of now, Lisata Therapeutics has not inherited any emissions data from a parent or related organisation, nor does it appear to be part of any industry-standard climate initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). In the context of the biotechnology industry, companies are increasingly focusing on sustainability and carbon reduction strategies. However, without specific commitments or data, it is unclear how Lisata Therapeutics aligns with these broader industry trends.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Lisata Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
